Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
MALT1 Protease Assay 2 from US Patent US20240018157: "CYCLIC COMPOUNDS AND METHODS OF USING SAME"
Assay data:134 Active, 176 Activity ≤ 1 µM, 176 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
MALT1 Protease Assay 1 from US Patent US20240018157: "CYCLIC COMPOUNDS AND METHODS OF USING SAME"
Assay data:52 Active, 53 Activity ≤ 1 µM, 53 Tested
Biochemical Assay from US Patent US20230391781: "MALT1 MODULATORS AND USES THEREOF"
Assay data:55 Active, 65 Activity ≤ 1 µM, 65 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
MALT-1 Biochemical Assay from US Patent US20230312601: "THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS"
Assay data:39 Active, 39 Activity ≤ 1 µM, 39 Tested
Affinity Biochemical interaction (TR-FRET assay (high salt)) EUB0000747a MALT1
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Affinity Biochemical interaction (TR-FRET assay (high salt)) EUB0000239b MALT1
Affinity Phenotypic Cellular interaction (Jurkat IL-2 (IL2-RGA PMA + anti-CD28)) EUB0000747a MALT1
Assay data:1 Active, 1 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
Affinity Phenotypic Cellular interaction (Jurkat IL-2 (IL2-RGA PMA + anti-CD28)) EUB0000239b MALT1
Inhibition of human MALT1 in human MCF7 cells assessed as MALT1 mediated cleavage of human A20 in cytosol by fluorescence microscopy
Assay data:3 Active, 3 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of human MALT1 assessed as cleavage of substrate using fluorescent labeled Ac-LRSR-Rh110 peptide as substrate incubated for 30 mins followed by substrate addition and measured after 3 to 4 hrs by FRET assay
Assay data:23 Active, 5 Activity ≤ 1 µM, 33 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of full length recombinant wild type MALT1 (unknown origin) using Ac-LVSR-AMC as substrate by HTS assay
Inhibition of MALT1 (329-824 residues) (unknown origin) using PT14 as substrate incubated for 60 mins by fluorescence based assay
Inhibition of GST-tagged human MALT1 (325-760 residues) expressed in Escherichia coli using Ac-LVSR-AMC as substrate by microplate reader based assay
Inhibition of MALT1 in human TMD8 cells assessed as decrease in RelB substrate cleavage at 8 uM preincubated for 30 mins followed by proteosome inhibitor MG-132 addition and measured after 2 hrs by Western blot analysis
Inhibition of MALT1 in human HBL1 cells assessed as decrease in RelB substrate cleavage at 8 uM preincubated for 30 mins followed by proteosome inhibitor MG-132 addition and measured after 2 hrs by Western blot analysis
Inhibition of N-terminal his-tagged GCN4 leucine zipper fused human MALT1 (340-281 residues) expressed in Escherichia coli using Ac-LVSR-AMC as substrate by HTS assay
Assay data:42 Active, 71 Tested
Inhibition of MALT1 (340 to 789 residues) (unknown origin) using Ac-LRSR-AMC as substrate by fluorescence based analysis
In Vitro Assay from US Patent US10954214: "Pyrazole derivatives as MALT1 inhibitors"
Assay data:436 Active, 380 Activity ≤ 1 µM, 444 Tested
Biochemical Protease Assay from US Patent US10888550: "Pyrazole derivatives as MALT1 inhibitors"
Assay data:33 Active, 25 Activity ≤ 1 µM, 33 Tested
Biological Assay from US Patent US10711036: "MALT1 inhibitors and uses thereof"
Assay data:85 Active, 86 Activity ≤ 1 µM, 87 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on